Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,817 signal articles · 264 in last 24h · 118,276 total before filter · latest 24m ago
264last 24h
1573last 7d
251● bullish (7d)
161● bearish (7d)
205publishers
AllMacro304Earnings635M&A97Regulatory28Product14Analyst24
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
MDB Q1 Deep Dive: Atlas and AI Momentum Drive Growth, Guidance Raised
StockStory81d agoneutral
MDB Q1 Deep Dive: Atlas and AI Momentum Drive Growth, Guidance Raised

Database platform company MongoDB (NASDAQ:MDB) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 25.2% year on year to $687.6 million. On top of that, next quarter’s revenue guidance ($731.5 million at the midpoint) was surprisingly good and 4.5% above what analysts were expecting. Its non-GAAP profit of $1.32 per share was 11.5% above analysts’ consensus estimates.

Assessing Applied Materials (AMAT) Valuation After Earnings Beat And New AI Chip Equipment Partnerships
Simply Wall St.82d agobullish
Assessing Applied Materials (AMAT) Valuation After Earnings Beat And New AI Chip Equipment Partnerships

Applied Materials (AMAT) is back in focus after beating quarterly earnings and revenue expectations and lifting its outlook as AI and data center demand intersects with fresh partnerships around advanced chip packaging and wafer cleaning. See our latest analysis for Applied Materials. Those AI and data center partnerships with Broadcom and SCREEN sit against strong momentum in the stock, with a 30 day share price return of 17.99%, a 1 year total shareholder return of 184.03% and a 5 year...

Should Stronger Ex‑VACCO Sales Guidance and Conference Outreach From RBC Bearings (RBC) Require Investor Action?
Simply Wall St.82d agoneutral
Should Stronger Ex‑VACCO Sales Guidance and Conference Outreach From RBC Bearings (RBC) Require Investor Action?

RBC Bearings Incorporated recently reported past fourth-quarter 2026 sales of US$518.0 million and net income of US$91.7 million, issued guidance for first-quarter fiscal 2027 net sales of US$500.0 million to US$510.0 million, and earlier this week presented at the KeyBanc Capital Markets 2026 Industrials & Basic Materials Conference in Boston. The combination of higher quarterly and full-year earnings, guidance that implies further sales growth even excluding VACCO, and active investor...

Snowflake (SNOW) Soars 36% as AI Propels Q1 Earnings
Insider Monkey82d agobullish
Snowflake (SNOW) Soars 36% as AI Propels Q1 Earnings

Snowflake Inc. (NYSE:SNOW) is one of the 11 Stocks Racking Up Monstrous Gains. Snowflake saw its share prices climb by 36.48 percent on Thursday to close at $239.20 apiece, as investors cheered the strong results of its earnings performance in the first quarter of fiscal year 2027. In an updated report, the company said that […]

Barclays resets Marvell stock price target after earnings
TheStreet82d agoneutral
Barclays resets Marvell stock price target after earnings

Marvell Technology has gained more than 200% in the past 12 months. It just reported record revenue, guided above expectations, and told investors that growth would accelerate every single quarter through the rest of the fiscal year. For Barclays analyst Tom O'Malley, that was enough to nearly ...

Best Buy (BBY) Beats Earnings Expectations, Shares Climb 15.8%
Insider Monkey82d agobullish
Best Buy (BBY) Beats Earnings Expectations, Shares Climb 15.8%

Best Buy Co. Inc. (NYSE:BBY) is one of the 11 Stocks Racking Up Monstrous Gains. Best Buy saw its share prices jump by 15.80 percent on Thursday to close at $74.74 apiece after posting a stellar earnings performance and beating its sales outlook for the first quarter of fiscal year 2027. In an earnings call […]

Why The Story Around Ionis Pharmaceuticals (IONS) Is Shifting After Fresh Analyst Targets And Guidance
Simply Wall St.82d agoneutral
Why The Story Around Ionis Pharmaceuticals (IONS) Is Shifting After Fresh Analyst Targets And Guidance

The fair value estimate for Ionis Pharmaceuticals has shifted from US$96.73 to US$100.92, a modest reset that puts fresh numbers around the stock. This move comes during an active period of Street research, with some firms lifting targets and others trimming them, reflecting different views on how to factor pipeline milestones and revenue guidance into valuation work. As you read on, you will see what is driving these updates and how to keep track of the evolving analyst narrative around...

Viasat Q4 Earnings Call Highlights
MarketBeat82d agoneutral
Viasat Q4 Earnings Call Highlights

Viasat (NASDAQ:VSAT) reported record backlog, modest revenue growth and positive free cash flow for fiscal 2026, while executives said the satellite communications company is positioning for growth from new satellite capacity, defense technology programs and a planned shared space infrastructure ven

Workday’s Q1 Earnings Call: Our Top 5 Analyst Questions
StockStory82d agoneutral
Workday’s Q1 Earnings Call: Our Top 5 Analyst Questions

Workday delivered a well-received Q1, as the market responded positively to growth in both revenue and profitability. Management attributed the strong performance to renewed momentum in its core business and the rapid adoption of its AI-powered agent solutions, which are helping customers automate HR and finance processes. CEO Aneel Bhusri pointed to this being Workday's best first quarter for new annual contract value (ACV) in five years, citing increased customer demand for AI-driven functiona